Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Maria Teresa Bochicchio, Barbara Izzo, Enrico Gottardi, Biagio De Angelis, Roberta Lorenzatti, Claudia Venturi, Francesca Crasto, Caterina De Benedittis, Filomena Daraio, Emanuela Ottaviani, Alessandro Volpengo, Giuseppe Saglio, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 1809.

https://doi.org/10.1182/blood.V124.21.1809.1809

Published: 2014

Journal Articles

Can Children and Adolescents With Chronic Myelogenous Leukemia Be Cured Without Stem Cell Transplant? A Single Center Experience

Fiorina Giona, Benedetta Siniscalchi, Maria Luisa Moleti, Massimiliano Rea, Deborah Marzella, Mauro Nanni, Enrico Gottardi, Anna Paola Iori, Daniela Diverio, Anna Maria Testi, Giuseppe Saglio, MD, Robin Foa'

Blood (2013) 122 (21): 4033.

https://doi.org/10.1182/blood.V122.21.4033.4033

Published: 2013

Journal Articles

Consistency Of RQ-PCR Analysis Results In Peripheral Blood and Bone Marrow Samples In Chronic Myeloid Leukemia Patients: Relevance From The Practical and Logistic Point Of View

Giovanna Rege-Cambrin, Carmen Fava, MD, Enrico Gottardi, BD, Filomena Daraio, PhD, Emilia Giugliano, PhD, Francesca Crasto, Roberta Lorenzatti, Alessandro Volpengo, Bruno Di Gioacchino, Giuseppe Saglio

Blood (2013) 122 (21): 2592.

https://doi.org/10.1182/blood.V122.21.2592.2592

Published: 2013

Journal Articles

A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease

Maya Koren-Michowitz, Avichai Shimoni, Filomena Daraio, Dr, Francesca Crasto, Dr, Roberta Lorenzatti, Dr, Yulia Volchek, Ninette Amariglio, Enrico Gottardi, MD, Giuseppe Saglio, MD, Arnon Nagler, MD

Blood (2012) 120 (21): 1690.

https://doi.org/10.1182/blood.V120.21.1690.1690

Published: 2012

Journal Articles

One Step Quantitative Molecular Approach for Detection of BCR/ABL Translocation and for Monitoring and Follow up of the Minimal Residual Disease in CML Patients Under Tyrosine Kines Inhibitors Treatment

Filomena Daraio, Dr, Davide Barberis, PhD, Francesca Crasto, Dr, Giovanna Rege-Cambrin, Cristina Olivo, PhD, Matteo Renzulli, PhD, Rosy Volpi, PhD, Roberta Lorenzatti, Dr, Carmen Fava, MD, Enrico Gottardi, MD, Giuseppe Saglio, MD

Blood (2012) 120 (21): 4435.

https://doi.org/10.1182/blood.V120.21.4435.4435

Published: 2012

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Massimo Breccia, MD, Roberto Latagliata, MD, Laura Cannella, MD, Ida Carmosino, MD, Enrico Gottardi, Daniela Cilloni, MD, Marco Vignetti, MD, Michelina Santopietro, MD, Marco Mancini, MD, Giuliana Alimena, MD

Blood (2009) 114 (22): 1777.

https://doi.org/10.1182/blood.V114.22.1777.1777

Published: 2009

Journal Articles

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Jerald P. Radich, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Enrico Gottardi, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Lan Beppu, Yaping Shou, MD, PhD, Ariful Haque, MS, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 1130.

https://doi.org/10.1182/blood.V114.22.1130.1130

Published: 2009

Journal Articles

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Simona Soverini, PhD, Enrico Gottardi, Lan Beppu, Martin C Müller, MD, Ariful Haque, MS, Yaping Shou, MD, PhD, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Giovanni Martinelli, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD

Blood (2009) 114 (22): 3292.

https://doi.org/10.1182/blood.V114.22.3292.3292

Published: 2009

Journal Articles

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

Francesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, Marilina Amabile, Gabriele Gugliotta, Angela Poerio, Massimo Breccia, Enrico Gottardi, Bruno Martino, Ivana Pierri, Fabrizio Quarantelli, Franca Radaelli, Giorgina Specchia, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani

Blood (2009) 114 (22): 2192.

https://doi.org/10.1182/blood.V114.22.2192.2192

Published: 2009

Journal Articles

Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib

Nunzio Iraci, Simona Soverini, Samuele Gherardi, Emanuele Valli, Fausto Castagnetti, Roberto Bernardoni, Gianantonio Rosti, Giuliano Della Valle, Francesca Palandri, Gabriele Gugliotta, Fabrizio Pane, Giuseppe Saglio, Nicola Esposito, Daniela Cilloni, Fabrizio Quarantelli, Enrico Gottardi, Michele Baccarani, Giovanni Martinelli, Giovanni Perini

Blood (2008) 112 (11): 3193.

https://doi.org/10.1182/blood.V112.11.3193.3193

Published: 2008

Journal Articles

Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.

Giovanna Rege-Cambrin, PhD, Stefano Ulisciani, MD, Giovanna Mattioli, MD, Carmen Fava, MD, Emilia Giugliano, BD, Vanessa Brunetto, BD, Enrico Gottardi, BD, Milena Fava, BD, Giuseppe Saglio, MD

Blood (2007) 110 (11): 1956.

https://doi.org/10.1182/blood.V110.11.1956.1956

Published: 2007

Journal Articles

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

Blood (2007) 109 (11): 4635–4640.

https://doi.org/10.1182/blood-2006-10-050054

Published: 2007

Includes: Supplemental data

Journal Articles

Persistent Molecular Remission in Patients Treated with Imatinib-IFNa Combination or Imatinib Monotherapy.

Monica Schippa, Enrico Gottardi, Debora Luzi, Lorenzo Falchi, Rita Emili, Ilaria Angeletti, Giorgia Desantis, Erminia Gentileschi, Paola Cerroni, Anna Marina Liberati

Blood (2006) 108 (11): 4784.

https://doi.org/10.1182/blood.V108.11.4784.4784

Published: 2006

Journal Articles

A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants.

Sabrina Colarossi, Simona Soverini, Alessandra Gnani, Michela Rondoni, Simona Gatto, Serena Merante, Enrico Gottardi, Daniela Cilloni, Pellegrino Musto, Mario Tiribelli, Roberta Zanotti, Giovanni Martinelli, Michele Baccarani

Blood (2006) 108 (11): 4849.

https://doi.org/10.1182/blood.V108.11.4849.4849

Published: 2006

Journal Articles

Philadelphia Chromosome (Ph’) Secondary Clones in Chronic Myeloid Leukemia (CML) Are Not Indicative of Resistance to IFNa- or Imatinib-Based Treatment Regimens.

Lorenzo Falchi, Paolo Prontera, Debora Luzi, Viola Festuccia, Rita Emili, Enrico Gottardi, Emilio Donti, Anna Marina Liberati

Blood (2006) 108 (11): 4806.

https://doi.org/10.1182/blood.V108.11.4806.4806

Published: 2006

Journal Articles

A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML.

Emilia Giugliano, BD, Dario Ferrero, MD, Carmen Fava, MD, Chiara Dellacasa, MD, Giovanna Mattioli, MD, Patrizia Scaravaglio, BD, Enrico Gottardi, Stefano Ulisciani, MD, Filomena Daraio, BD, Giuseppe Saglio, MD, Giovanna Rege-Cambrin, MD

Blood (2006) 108 (11): 4910.

https://doi.org/10.1182/blood.V108.11.4910.4910

Published: 2006

Journal Articles

Overexpression of the p65 Subunit of NF-kB and IkB Mediated Nuclear Sequestration of p53 as Common Events in Philadelphia Positive and Negative Chronic Myeloid Leukemia.

Alessandro Morotti, MD, Daniela Cilloni, MD, PhD, Riccardo Taulli, PhD, Francesca Arruga, PhD, Renata Catalano, PhD, Francesca Messa, PhD, Ilaria Defilippi, PhD, Sonia Carturan, PhD, Sara Capella, MD, Valentina Rosso, PhD, Annalisa Chiarenza, MD, Marisa Pautasso, MD, Enrico Gottardi, PhD, Carola Ponzetto, PhD, Giuseppe Saglio, MD

Blood (2005) 106 (11): 2871.

https://doi.org/10.1182/blood.V106.11.2871.2871

Published: 2005

Journal Articles

The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia.

Daniela Cilloni, MD, PhD, Francesca Messa, PhD, Giovanni Martinelli, MD, Enrico Gottardi, PhD, Ilaria Defilippi, PhD, Francesca Arruga, PhD, Sonia Carturan, PhD, Emanuela Messa, MD, Emilia Giugliano, PhD, Valentina Rosso, PhD, Serena Merante, MD, Annalisa Charenza, MD, Michela Rondoni, MD, Emanuela Ottaviani, PhD, Mario Tiribelli, MD, Fabrizio Pane, MD, Michele Baccarani, MD, Giuseppe Saglio, MD

Blood (2005) 106 (11): 3251.

https://doi.org/10.1182/blood.V106.11.3251.3251

Published: 2005

Journal Articles

Standardization of WT1 mRNA Quantification for Minimal Residual Disease (MRD) Monitoring in Acute Leukemia Patients: A European LeukemiaNet Concerted Action.

Enrico Gottardi, Daniela Cilloni, MD, Sarah Daly, S. Green, Niels Pallisgaard, P. Hokland, MD, M. Ostergaard, C. Nyvold, J. Nomdedeu, MD, Fabrizio Pane, MD, Susanne Schnittger, Vincent Van der Velden, Kalid Tobal, Y. Yin Jal, Fabienne Hermitte, Teo De Witte, R. Hehlmann, Giuseppe Saglio, MD, David Grimwade, MD

Blood (2005) 106 (11): 3295.

https://doi.org/10.1182/blood.V106.11.3295.3295

Published: 2005

NARROW

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Can Children and Adolescents With Chronic Myelogenous Leukemia Be Cured Without Stem Cell Transplant? A Single Center Experience

Consistency Of RQ-PCR Analysis Results In Peripheral Blood and Bone Marrow Samples In Chronic Myeloid Leukemia Patients: Relevance From The Practical and Logistic Point Of View

A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease

One Step Quantitative Molecular Approach for Detection of BCR/ABL Translocation and for Monitoring and Follow up of the Minimal Residual Disease in CML Patients Under Tyrosine Kines Inhibitors Treatment

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib

Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

Persistent Molecular Remission in Patients Treated with Imatinib-IFNa Combination or Imatinib Monotherapy.

A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants.

Philadelphia Chromosome (Ph’) Secondary Clones in Chronic Myeloid Leukemia (CML) Are Not Indicative of Resistance to IFNa- or Imatinib-Based Treatment Regimens.

A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML.

Overexpression of the p65 Subunit of NF-kB and IkB Mediated Nuclear Sequestration of p53 as Common Events in Philadelphia Positive and Negative Chronic Myeloid Leukemia.

The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia.

Standardization of WT1 mRNA Quantification for Minimal Residual Disease (MRD) Monitoring in Acute Leukemia Patients: A European LeukemiaNet Concerted Action.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only